Boundless Bio, Inc. (BOLD) reported a net loss of $58.2 million for the year ended December 31, 2025, compared to a net loss of $65.4 million for the previous year. Research and development expenses decreased to $44.8 million from $55.3 million, primarily due to reduced spending on the STARMAP and POTENTIATE trials, partially offset by increased investment in the BBI-940 program. General and administrative expenses increased slightly to $18.7 million from $18.0 million, driven by higher facilities-related costs associated with the new corporate headquarters, offset by lower personnel costs.
The company's strategic shift towards prioritizing the BBI-940 program led to the discontinuation of the monotherapy and combination arms of BBI-355 in the POTENTIATE trial, as well as the cessation of enrollment in the BBI-355 and BBI-825 combination arm. The STARMAP trial for BBI-825 was also wound down in 2025. These decisions were based on market considerations, clinical data, and a focus on advancing BBI-940, a novel kinesin degrader, through clinical development. In February 2026, Boundless Bio initiated the KOMODO-1 trial, a Phase 1 clinical trial for BBI-940 in patients with ER+/HER2- metastatic breast cancer and TNBC-LAR.
As of March 8, 2026, Boundless Bio had 28 full-time employees, with 16 in research and development and 12 in general and administrative roles. The company's intellectual property portfolio included 24 patent families, encompassing pending U.S. provisional and non-provisional applications, issued U.S. patents, and applications in various international jurisdictions. The company continues to leverage its Spyglass platform to identify new cancer drug targets and explore additional development opportunities for BBI-940.
Boundless Bio anticipates that its existing cash, cash equivalents, and short-term investments of $117.6 million as of December 31, 2025, will be sufficient to fund operations into the second half of 2028. This projection is based on the current operating plan, which includes the advancement of BBI-940 through initial proof-of-concept clinical data readout. The company expects to continue relying on third-party manufacturers for its ecDTx and related raw materials. The company may seek additional funding through equity offerings, debt financings, or strategic collaborations to support its long-term business objectives.
About Boundless Bio, Inc.
Boundless Bio, Inc. is a clinical-stage oncology company focused on developing therapies targeting extrachromosomal DNA (ecDNA), a key driver of oncogene amplification in cancer. Its proprietary platform identifies vulnerabilities in ecDNA biology to create small molecule ecDNA-directed therapeutics (ecDTx). The company's lead drug, BBI-355, a CHK1 inhibitor, aims to treat ecDNA-driven cancers resistant to existing therapies, addressing a significant unmet medical need across multiple tumor types.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.